SYNT 001

Drug Profile

SYNT 001

Alternative Names: SYNT-001

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Syntimmune
  • Class Immunotherapies
  • Mechanism of Action Fc receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Autoimmune disorders; Pemphigus

Most Recent Events

  • 09 Dec 2017 Pharmacodynamics, pharmacokinetics and adverse events data from a phase I trial in Autoimmune disorders presented at the 59th Annual Meeting and Exposition of the American Society of Hematology (ASH-2017)
  • 04 Dec 2017 Applied BioMath and Syntimmune agree to support development of SYNT 001 for IgG-mediated autoimmune diseases
  • 01 Aug 2017 Syntimmune initiates enrolment in a phase I trial in Autoimmune disorders in USA (IV) (NCT03075878)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top